Scarinci Hollenbeck, LLC, LLCScarinci Hollenbeck, LLC, LLC

Firm Insights

Will IP Rights Hamper Access to a COVID-19 Vaccine or Not?

Author: Scarinci Hollenbeck, LLC

Date: October 21, 2020

Key Contacts

Back

Widespread access to a safe and effective COVID-19 vaccine is the key to getting back to normal, according to health experts…

Will IP Rights Hamper Access to a COVID-19 Vaccine?

Widespread access to a safe and effective COVID-19 vaccine is the key to getting back to normal, according to health experts. However, some are questioning whether patent rights could serve as a “barrier” to access to COVID-19 vaccines and treatments.

Pharmaceutical companies are generally entitled to protect their intellectual property by obtaining patents for vaccines and treatments they develop. However, the need to quickly respond to the COVID-19 pandemic has raised questions over the proper balance between IP rights and serving the public good.

Bayh-Dole Act

The Bayh-Dole Act is being touted by some as the answer to access concerns involving COVID-19 vaccines and treatment. The law applies to inventions springing from government-funded research, and its stated goal is to “ensure that the Government obtains sufficient rights in federally supported inventions to meet the needs of the Government and protect the public against nonuse or unreasonable use of inventions.” 

Under the Bayh-Dole Act, a nonprofit organization or small business may elect to retain title to any “subject invention” generated with federal financial assistance. However, they must comply with certain requirements, including the obligation to disclose U.S. federal government support in patent applications. The disclosure requirements are also set forth in regulations issued by the U.S. Patent and Trademark Office (USPTO).

One of the most controversial provisions of the Bayh-Dohl Act involves the federal government’s march-in rights, which provide a Federal agency with the authority, in certain very limited and specified circumstances, to make sure that a federally funded invention is made available to the public. The march-in provisions are set out in 35 U.S. Code § 203, which states that:

With respect to any subject invention in which a small business firm or nonprofit organization has acquired title under this chapter, the Federal agency under whose funding agreement the subject invention was made shall have the right, in accordance with such procedures as are provided in regulations promulgated hereunder to require the contractor, an assignee or exclusive licensee of a subject invention to grant a nonexclusive, partially exclusive, or exclusive license in any field of use to a responsible applicant or applicants, upon terms that are reasonable under the circumstances, and if the contractor, assignee, or exclusive licensee refuses such request, to grant such a license itself (under certain enumerated rights).

Investigation into COVID-19 Treatment Development

In August, 34 state attorneys general sent a letter requesting the federal government to exercise march-in drug rights for Gilead Sciences’ COVID-19 treatment remdesivir. “Here, we think it is clear that Gilead has not established a reasonable price, nor has it met the health and safety needs of the public given the COVID-19 pandemic,” the letter states. “We urge the federal government to use its march-in rights to help increase the supply of this drug and lower the price so it is accessible to our state residents.”

USPTO Response to Access Concerns

To date, the USPTO has downplayed concerns about barriers to access. In remarks at IP Week on August 27, 2020, USPTO Director Andrei Iancu said that the public should be concerned by statements like “IP is a barrier to innovation” or that drastic measures like compulsory licenses should be imposed in light of the COVID-19 pandemic. Director Iancu emphasized that evidence of need must be shown before any such measure is taken, stating:

As it turns out, the evidence to date shows that IP is a catalyst for, and not a barrier to, the development of vital technologies needed for the current pandemic. The evidence also shows that voluntary actions are being undertaken by many rights holders during this crisis, including: innovative licensing arrangements, the publication of scientific data on a free-to-use basis, the publication of technical specifications that enable others to manufacture, and the voluntary renouncement of enforcement of patents in certain jurisdictions during the crisis. 

Director Iancu’s confidence in companies “doing the right thing” was recently validated. On October 8, Moderna clarified its position on COVID-19-related IP. In a statement, the company committed to making its IP available to other vaccine manufacturers in an effort to prevent barriers to access. The company wrote:

Accordingly, while the pandemic continues, Moderna will not enforce our COVID-19 related patents against those making vaccines intended to combat the pandemic. Further, to eliminate any perceived IP barriers to vaccine development during the pandemic period, upon request we are also willing to license our intellectual property for COVID-19 vaccines to others for the post-pandemic period.

Key Takeaway

The COVID-19 pandemic has the potential to spur innovation that may continue to benefit the world once the emergency has passed. How companies and the federal government balance IP rights and public access going forward will continue to be a closely watched issue.

If you have questions, please contact us

If you have any questions or if you would like to discuss the matter further, please contact the Scarinci Hollenbeck attorney with whom you work, at 201-896-4100.

No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

Scarinci Hollenbeck, LLC, LLC

Related Posts

See all
Short Form Merger: Streamlining the Process for Businesses post image

Short Form Merger: Streamlining the Process for Businesses

Merging two companies is a complex legal and business transaction. A short form merger, in which an acquiring company merges with a subsidiary corporation, offers a more streamlined process. However, like all M&A transactions, it is important to understand the legal nuances and proper due diligence in mergers and acquisitions. What Is a Short Form […]

Author: Dan Brecher

Link to post with title - "Short Form Merger: Streamlining the Process for Businesses"
Tariff Response Options for Small Businesses Facing Financial Distress post image

Tariff Response Options for Small Businesses Facing Financial Distress

The Trump Administration’s new tariffs are having an oversized impact on small businesses, which already tend to operate on razor thin margins. Many businesses have been forced to raise prices, find new suppliers, lay off staff, and delay growth plans. For businesses facing even more dire financial circumstances, there are additional tariff response options, including […]

Author: Brian D. Spector

Link to post with title - "Tariff Response Options for Small Businesses Facing Financial Distress"
Common Causes of Partnership Disputes and How to Resolve Them post image

Common Causes of Partnership Disputes and How to Resolve Them

Business partnerships, much like marriages, function exceptionally well when partners are aligned but can become challenging when disagreements arise. Partnership disputes often stem from conflicts over business strategy, financial management, and unclear role definitions among partners. Understanding Business Partnership Conflicts Partnership conflicts place significant stress on businesses, making proactive measures essential. Partnerships should establish detailed […]

Author: Christopher D. Warren

Link to post with title - "Common Causes of Partnership Disputes and How to Resolve Them"
President Trump's Termination of Member Gwynne Wilcox post image

President Trump's Termination of Member Gwynne Wilcox

On January 28, 2025, the Trump Administration terminated Gwynne Wilcox from her position as a Member of the National Labor Relations Board (NLRB or the Board). Gwynne Wilcox, a union side lawyer for Levy Ratner, was confirmed to the Board for an original term in 2021 and confirmed again for a successive five-year term expiring […]

Author: Matthew F. Mimnaugh

Link to post with title - "President Trump's Termination of Member Gwynne Wilcox"

No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

Sign up to get the latest from our attorneys!

Explore What Matters Most to You.

Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.

Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.

Let`s get in touch!

* The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!